Novartis Venture Fund
Florent Gros is a Managing Director of the Novartis Venture Funds in Basel, Switzerland. He serves on the boards of AIT, Atlas Genetics, Gensight Biologics, Merus, MyoPower, Opsona, and Vaxin, and his prior investments into Evolva (CH), Cellerix (BE) and Neovacs (FR) resulted in successful listings on European stock markets.
Florent brings experience with intellectual property, licensing, and M&A. Before his venture career, Florent worked 14 years in intellectual property, holding senior positions at Nestlé, Aventis Pasteur and Novartis. He was in the leadership team of several pharmaceutical product developments, was the head of IP Transactions at Novartis, and was particularly involved in the biologics strategies. His startup experience includes managing patent groups, licensing assets either from or to startups, and managing intellectual property conflicts with startups.
Education, Personal, and Fellowship
Florent is a graduate of the Louis Pasteur University (France), holding a biotechnology engineering degree with diploma thesis made at Glaxo Vaccine (Belgium). Florent is also a European and French patent attorney, and holds a Master's in private law from the University of Haute Alsace (France).
Florent Gros is a member of Kauffman Fellows Class 12 and served his fellowship under mentor Reinhard Ambros at the Novartis Venture Funds.